Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 11/20 | 0.63 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521156 | 0.92 | NR3C1 (0.63) | NR3C1ADAMTS4MMP13ALDH1A1HTR7 | |
| SCHEMBL13889061 | 0.85 | NR3C1 (0.46) | NR3C1ADAMTS4MMP13FFAR1FFAR4 | |
| SCHEMBL4507730 | 0.84 | NR3C1 (0.66) | NR3C1ALDH1A1 | |
| SCHEMBL4517669 | 0.82 | NR3C1 (0.73) | NR3C1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4516532 | 0.78 | NR3C1 (0.57) | NR3C1ADAMTS4MMP13FFAR1FFAR4 | |
| SCHEMBL4517545 | 0.77 | NR3C1 (1.00) | NR3C1 | |
| SCHEMBL4501289 | 0.77 | NR3C1 (0.61) | NR3C1ALDH1A1HTR7 | |
| SCHEMBL4515242 | 0.77 | NR3C1 (0.69) | NR3C1HTR7 | |
| SCHEMBL4516862 | 0.76 | NR3C1 (1.00) | NR3C1 | |
| SCHEMBL4515955 | 0.76 | NR3C1 (0.66) | NR3C1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | NR3C1 1/4885ADAMTS4 3658/4885MMP13 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.